Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04293185
Recruitment Status : Recruiting
First Posted : March 3, 2020
Last Update Posted : July 19, 2022
Sponsor:
Information provided by (Responsible Party):
bluebird bio

Brief Summary:

This is a non-randomized, open-label, multi-site, single-dose, Phase 3 study in approximately 35 adults and pediatric subjects ≥2 and ≤50 years of age with sickle cell disease (SCD). The study will evaluate hematopoietic stem cell (HSC) transplantation (HSCT) using bb1111 (also known as LentiGlobin BB305 Drug Product for SCD).

On 20 December 2021, bluebird bio., Inc. announced that the FDA placed the study on partial clinical hold for pediatric patients (patients less than 18 years of age). This suspension includes that no new enrollment, cell collection, conditioning, or drug product infusion be initiated in pediatric patients. The study remains open to patients 18 years of age and older.


Condition or disease Intervention/treatment Phase
Sickle Cell Disease Genetic: bb1111 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the BB305 Lentiviral Vector in Subjects With Sickle Cell Disease
Actual Study Start Date : February 14, 2020
Estimated Primary Completion Date : February 2025
Estimated Study Completion Date : September 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: bb1111

Subjects will receive treatment with a single dose of Drug Product manufactured with autologous CD34+ hematopoietic stem cells collected by plerixafor mobilization and apheresis, transduced with BB305 lentiviral vector (LVV) encoding the human beta-A-T87Q globin gene.

Plerixafor mobilization and apheresis will also be used for collection of rescue cells.

Genetic: bb1111
Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
Other Names:
  • lovotibeglogene autotemcel
  • lovo-cel
  • LentiGlobin BB305 Drug Product for SCD
  • autologous CD34+ cell-enriched population from patients with SCD that contains HSCs transduced with BB305 LVV encoding the βA-T87Q-globin gene, suspended in cryopreservation solution




Primary Outcome Measures :
  1. VOE-CR [ Time Frame: 6-18 months post-transplant ]
    Proportion of subjects achieving complete resolution of VOEs between 6 months and 18 months after drug product infusion


Secondary Outcome Measures :
  1. sVOE-CR [ Time Frame: 6-18 months post-transplant ]
    Proportion of subjects achieving complete resolution of severe vaso-occlusive events, between 6 months and 18 months after drug product infusion

  2. Proportion of subjects achieving Globin Response [ Time Frame: 6-24 months post-transplant ]

    Globin Response, defined as meeting the following criteria for a continuous period of at least 6 months after drug product infusion:

    1. Weighted average HbAT87Q percentage of non-transfused total Hb* ≥30% AND
    2. Weighted average non-transfused total Hb* increase of ≥3 g/dL compared to baseline total Hb* OR weighted average non-transfused total Hb* ≥10 g/dL

      • non-transfused total Hb is the total g/dL of HbS + HbF + HbA2 + HbAT87Q

  3. Change in the annualized number of VOEs in the 24 months after drug product infusion compared to the 24 months prior to Informed Consent [ Time Frame: 1-24 months post-transplant ]
  4. Change in the annualized number of severe VOEs in the 24 months after drug product infusion compared to the 24 months prior to Informed Consent. [ Time Frame: 1-24 months post-transplant ]
  5. VOE-CR24 [ Time Frame: 6-24 months post-transplant ]
    Proportion of subjects achieving complete resolution of VOEs between 6 months and 24 months after drug product infusion

  6. sVOE-CR24 [ Time Frame: 6-24 months post-transplant ]
    Proportion of subjects achieving complete resolution of severe VOEs between 6 months and 24 months after drug product infusion

  7. sVOE-75 [ Time Frame: 1-24 months post-transplant ]
    Proportion of subjects achieving at least a 75% reduction in annualized severe VOEs in the 24 months after drug product administration compared to the 24 months prior to Informed Consent.

  8. Weighted average non-transfused total Hb [ Time Frame: Month 6, 12, 18 and 24 post-transplant ]
  9. Weighted average HbS percentage of non-transfused total Hb [ Time Frame: Month 6, 12, 18 and 24 post-transplant ]
  10. Weighted average HbS percentage of non-transfused total Hb ≤70%, ≤60%, ≤50% [ Time Frame: Month 6, 12, 18 and 24 post-transplant ]
  11. Weighted average HbAT87Q percentage of non-transfused total Hb [ Time Frame: Month 6, 12, 18 and 24 post-transplant ]
  12. Weighted average non-HbS percentage of non-transfused total Hb [ Time Frame: Month 6, 12, 18 and 24 post-transplant ]
  13. Average and median of non-transfused total Hb [ Time Frame: 1-24 months post-transplant ]
  14. Average and median of HbS percentage of non-transfused total Hb [ Time Frame: 1-24 months post-transplant ]
  15. Average and median of HbAT87Q percentage of non-transfused total Hb [ Time Frame: 1-24 months post-transplant ]
  16. Average and median of non-HbS percentage of non-transfused total Hb [ Time Frame: 1-24 months post-transplant ]
  17. Change from baseline in absolute reticulocyte count [ Time Frame: 1-24 months post-transplant ]
  18. Change from baseline in percent reticulocytes [ Time Frame: 1-24 months post-transplant ]
  19. Change from baseline in percent erythrocytes [ Time Frame: 1-24 months post-transplant ]
  20. Change from baseline in total bilirubin [ Time Frame: 1-24 months post-transplant ]
  21. Change from baseline in haptoglobin [ Time Frame: 1-24 months post-transplant ]
  22. Change from baseline in lactate dehydrogenase [ Time Frame: 1-24 months post-transplant ]
  23. Change from baseline in ferritin [ Time Frame: 1-24 months post-transplant ]
  24. Change from baseline in liver iron content [ Time Frame: 1-24 months post-transplant ]
  25. Change from baseline in cardiac iron content (if assessed at baseline) [ Time Frame: 1-24 months post-transplant ]
  26. Change from baseline in erythropoietin [ Time Frame: 1-24 months post-transplant ]
  27. Change from baseline in serum transferrin receptor [ Time Frame: 1 - 24 months post-transplant ]
  28. Change from baseline in annualized frequency of packed red blood cell (pRBC) transfusions [ Time Frame: 6-24 months post-transplant ]
  29. Change from baseline in annualized volume of pRBC transfusions [ Time Frame: 6-24 months post-transplant ]
  30. Change from baseline in TCD velocity at Month 12 and Month 24 (for subjects ≤ 16 years old at Informed Consent) [ Time Frame: Month 12 and Month 24 post-transplant ]
  31. Change from baseline in meters walked during the 6-minute walk test [ Time Frame: 1 - 24 months post-transplant ]
  32. Change from baseline in annualized number of SCD-related hospital admissions [ Time Frame: 1 - 24 months post-transplant ]
  33. Change from baseline in annualized number of total days hospitalized [ Time Frame: 1 - 24 months post-transplant ]
  34. Change from baseline in patient-reported quality of life, as measured by PROMIS-57 Version 2.1 for subjects ≥ 18 years of age and PROMIS Pediatric Profile/Parent Proxy Profile 49 Version 2.0 for subjects < 18 years of age [ Time Frame: 1 - 24 months post-transplant ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 50 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have a diagnosis of SCD, with either βS/βS, βS/β0, or βS/β+ genotype.
  • Be ≥2 and ≤50 years of age at time of consent.
  • Weigh a minimum of 6 kg.
  • Have a Karnofsky performance status of ≥60 (≥16 years of age) or a Lansky performance status of ≥60 (<16 years of age).
  • Be treated and followed for at least the past 24 months prior to Informed Consent in medical center(s) that maintained detailed records on sickle cell disease history.
  • In the setting of appropriate supportive care measures (e.g., pain management plan), have experienced at least 4 protocol-defined VOEs in the 24 months prior to informed consent.
  • Have either experienced HU failure at any point in the past or must have intolerance to HU (intolerance is defined as the patient being unable to continue to take HU per PI judgment).
  • Female and male subjects of childbearing potential agree to use 1 method of highly effective contraception from Screening to at least 6 months after drug product infusion.
  • Provision of written informed consent for this study by subject, or as applicable, subject's parent(s)/legal guardian(s).

Exclusion Criteria:

  • Subjects for whom allogeneic hematopoietic stem cell transplantation (allo-HSCT) is medically appropriate per PI judgment and a willing, human leukocyte antigen (HLA)-matched related hematopoietic stem cell donor is available.
  • Severe cerebral vasculopathy, defined by any history of overt ischemic or hemorrhagic stroke, a history of abnormal transcranial Doppler (TCD) or TCD imaging (TCDI) for subjects ≤ 16 years of age (e.g. TCD velocity >200 cm/sec) requiring ongoing chronic transfusions, a Screening TCD or TCDI velocity > 200 cm/sec (central read), a Screening MRA showing > 50% stenosis or occlusion in the circle of Willis (central read), or a Screening MRA showing the presence of Moyamoya (central read).
  • Positive for presence of human immunodeficiency virus type 1 or 2 (HIV-1 or HIV-2), hepatitis B, hepatitis C, human T-lymphotropic virus-1 (HTLV-1), active syphilis.
  • Clinically significant, active bacterial, viral, fungal, or parasitic infection
  • Advanced liver disease, such as

    1. clear evidence of liver cirrhosis, active hepatitis or significant fibrosis (based on MRI or liver biopsy)
    2. liver iron concentration ≥15 mg/g unless liver biopsy shows no evidence of cirrhosis, active hepatitis or significant fibrosis
  • Inadequate bone marrow function, as defined by an absolute neutrophil count of <1×10^9/L (<0.5×10^9/L for subjects on hydroxyurea treatment) or a platelet count <100×10^9/L.
  • Any contraindications to the use of plerixafor during the mobilization of hematopoietic stem cells and any contraindications to the use of busulfan and any other medicinal products required during the myeloablative conditioning, including hypersensitivity to the active substances or to any of the excipients.
  • Patients needing therapeutic anticoagulation treatment during the period of conditioning through platelet engraftment
  • Unable to receive pRBC transfusion.
  • Prior receipt of an allogeneic transplant.
  • Prior receipt of gene therapy.
  • Any prior or current malignancy or immunodeficiency disorder, except previously treated, non-life threatening, cured tumors such as squamous cell carcinoma of the skin.
  • Immediate family member with a known or suspected Familial Cancer Syndrome.
  • Female subject is breastfeeding, pregnant or will attempt to become pregnant from Screening to at least 6 months after drug product infusion.
  • Any other condition that would render the subject ineligible for HSCT.
  • Participation in another clinical study with an investigational drug within 30 days of screening.
  • Presence of a chromosomal abnormality or genetic mutation that may put the subject at an increased risk of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) per Investigator's judgment.
  • Presence of genetic mutations that result in the inactivation of 2 or more α-globin genes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04293185


Contacts
Layout table for location contacts
Contact: bluebird bio +1-339-499-9300 clinicaltrials@bluebirdbio.com

Locations
Layout table for location information
United States, Alabama
University of Alabama Active, not recruiting
Birmingham, Alabama, United States, 35233
United States, District of Columbia
Children's National Hospital Recruiting
Washington, District of Columbia, United States, 20010
United States, Massachusetts
Tufts Medical Center Recruiting
Boston, Massachusetts, United States, 02111
United States, Minnesota
University of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55455
United States, New Jersey
Hackensack University Medical Center Recruiting
Hackensack, New Jersey, United States, 07601
United States, North Carolina
Duke University Recruiting
Durham, North Carolina, United States, 27705
United States, Texas
Baylor College of Medicine/Texas Children's Hospital Recruiting
Houston, Texas, United States, 77030
United States, Virginia
Virginia Commonwealth University (VCU) Recruiting
Richmond, Virginia, United States, 23219
United States, Washington
Fred Hutchinson Cancer Research Center Recruiting
Seattle, Washington, United States, 98109
Sponsors and Collaborators
bluebird bio
Investigators
Layout table for investigator information
Study Director: Anjulika Chawla, MD, FAAP bluebird bio, Inc.
Layout table for additonal information
Responsible Party: bluebird bio
ClinicalTrials.gov Identifier: NCT04293185    
Other Study ID Numbers: HGB-210
First Posted: March 3, 2020    Key Record Dates
Last Update Posted: July 19, 2022
Last Verified: July 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn